Cargando…

Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory

Genotyping epidermal growth factor receptor (EGFR) gene in patients with advanced non-small cell lung cancers (NSCLC) is essential for identifying those patients who may benefit from targeted therapies. Systemically evaluating EGFR mutation detection rates of different methods currently used in clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Linlin, Zhao, Weiwei, Li, Xiaoxia, Zhang, Shangfei, Zhou, Changhong, Zhou, Danyan, Ou, Xiaohua, Xu, Yanyan, Tang, Yuanxiao, Ou, Xiaoyong, Hu, Changming, Ding, Xiangdong, Luo, Pifu, Yu, Shihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262202/
https://www.ncbi.nlm.nih.gov/pubmed/34257561
http://dx.doi.org/10.3389/pore.2021.602726
_version_ 1783719144605089792
author Mao, Linlin
Zhao, Weiwei
Li, Xiaoxia
Zhang, Shangfei
Zhou, Changhong
Zhou, Danyan
Ou, Xiaohua
Xu, Yanyan
Tang, Yuanxiao
Ou, Xiaoyong
Hu, Changming
Ding, Xiangdong
Luo, Pifu
Yu, Shihui
author_facet Mao, Linlin
Zhao, Weiwei
Li, Xiaoxia
Zhang, Shangfei
Zhou, Changhong
Zhou, Danyan
Ou, Xiaohua
Xu, Yanyan
Tang, Yuanxiao
Ou, Xiaoyong
Hu, Changming
Ding, Xiangdong
Luo, Pifu
Yu, Shihui
author_sort Mao, Linlin
collection PubMed
description Genotyping epidermal growth factor receptor (EGFR) gene in patients with advanced non-small cell lung cancers (NSCLC) is essential for identifying those patients who may benefit from targeted therapies. Systemically evaluating EGFR mutation detection rates of different methods currently used in clinical setting will provide valuable information to clinicians and laboratory scientists who take care of NSCLC patients. This study retrospectively reviewed the EGFR data obtained in our laboratory in last 10 years. A total of 21,324 NSCLC cases successfully underwent EGFR genotyping for clinical therapeutic purpose, including 5,244 cases tested by Sanger sequencing, 13,329 cases tested by real-time PCR, and 2,751 tested by next-generation sequencing (NGS). The average EGFR mutation rate was 45.1%, with 40.3% identified by Sanger sequencing, 46.5% by real-time PCR and 47.5% by NGS. Of these cases with EGFR mutations identified, 93.3% of them harbored a single EGFR mutation (92.1% with 19del or L858R, and 7.9% with uncommon mutations) and 6.7% harbored complex EGFR mutations. Of the 72 distinct EGFR variants identified in this study, 15 of them (single or complex EGFR mutations) were newly identified in NSCLC. For these cases with EGFR mutations tested by NGS, 65.3% of them also carried tumor-related variants in some non-EGFR genes and about one third of them were considered candidates of targeted drugs. NGS method showed advantages over Sanger sequencing and real-time PCR not only by providing the highest mutation detection rate of EGFR but also by identifying actionable non-EGFR mutations with targeted drugs in clinical setting.
format Online
Article
Text
id pubmed-8262202
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82622022021-07-12 Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory Mao, Linlin Zhao, Weiwei Li, Xiaoxia Zhang, Shangfei Zhou, Changhong Zhou, Danyan Ou, Xiaohua Xu, Yanyan Tang, Yuanxiao Ou, Xiaoyong Hu, Changming Ding, Xiangdong Luo, Pifu Yu, Shihui Pathol Oncol Res Society Journal Archive Genotyping epidermal growth factor receptor (EGFR) gene in patients with advanced non-small cell lung cancers (NSCLC) is essential for identifying those patients who may benefit from targeted therapies. Systemically evaluating EGFR mutation detection rates of different methods currently used in clinical setting will provide valuable information to clinicians and laboratory scientists who take care of NSCLC patients. This study retrospectively reviewed the EGFR data obtained in our laboratory in last 10 years. A total of 21,324 NSCLC cases successfully underwent EGFR genotyping for clinical therapeutic purpose, including 5,244 cases tested by Sanger sequencing, 13,329 cases tested by real-time PCR, and 2,751 tested by next-generation sequencing (NGS). The average EGFR mutation rate was 45.1%, with 40.3% identified by Sanger sequencing, 46.5% by real-time PCR and 47.5% by NGS. Of these cases with EGFR mutations identified, 93.3% of them harbored a single EGFR mutation (92.1% with 19del or L858R, and 7.9% with uncommon mutations) and 6.7% harbored complex EGFR mutations. Of the 72 distinct EGFR variants identified in this study, 15 of them (single or complex EGFR mutations) were newly identified in NSCLC. For these cases with EGFR mutations tested by NGS, 65.3% of them also carried tumor-related variants in some non-EGFR genes and about one third of them were considered candidates of targeted drugs. NGS method showed advantages over Sanger sequencing and real-time PCR not only by providing the highest mutation detection rate of EGFR but also by identifying actionable non-EGFR mutations with targeted drugs in clinical setting. Frontiers Media S.A. 2021-04-07 /pmc/articles/PMC8262202/ /pubmed/34257561 http://dx.doi.org/10.3389/pore.2021.602726 Text en Copyright © 2021 Mao, Zhao, Li, Zhang, Zhou, Zhou, Ou, Xu, Tang, Ou, Hu, Ding, Luo and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Society Journal Archive
Mao, Linlin
Zhao, Weiwei
Li, Xiaoxia
Zhang, Shangfei
Zhou, Changhong
Zhou, Danyan
Ou, Xiaohua
Xu, Yanyan
Tang, Yuanxiao
Ou, Xiaoyong
Hu, Changming
Ding, Xiangdong
Luo, Pifu
Yu, Shihui
Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory
title Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory
title_full Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory
title_fullStr Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory
title_full_unstemmed Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory
title_short Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory
title_sort mutation spectrum of egfr from 21,324 chinese patients with non-small cell lung cancer (nsclc) successfully tested by multiple methods in a cap-accredited laboratory
topic Society Journal Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262202/
https://www.ncbi.nlm.nih.gov/pubmed/34257561
http://dx.doi.org/10.3389/pore.2021.602726
work_keys_str_mv AT maolinlin mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory
AT zhaoweiwei mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory
AT lixiaoxia mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory
AT zhangshangfei mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory
AT zhouchanghong mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory
AT zhoudanyan mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory
AT ouxiaohua mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory
AT xuyanyan mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory
AT tangyuanxiao mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory
AT ouxiaoyong mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory
AT huchangming mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory
AT dingxiangdong mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory
AT luopifu mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory
AT yushihui mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory